<br>        Inclusion Criteria:<br><br>          1. Age > 18 years<br><br>          2. Histologic diagnosis of squamous cell carcinoma of the oral cavity including the lip,<br>             floor of mouth, anterior 2/3 of tongue, alveolus and gingiva, buccal mucosa, hard<br>             palate and retromolar trigone<br><br>          3. Subjects must have undergone primary gross total resection (no re-resected patients<br>             are allowed) with fulfillment of at least 1 of the following histologic criteria for<br>             high-risk disease:<br><br>               -  Histologic involvement of 2 or more regional lymph nodes<br><br>               -  Any lymph node with histologic extracapsular extension (ECS)<br><br>               -  Close (<3mm) or positive surgical margins on microscopic evaluation with no gross<br>                  residual tumor<br><br>          4. No evidence of locoregional disease or distant metastases at screening. Subjects must<br>             have negative scans (CT, CT-PET or MRI) for locoregional recurrence, brain or lung<br>             metastases. A negative biopsy will be mandated in patients with a positive scan. Other<br>             evaluations should be performed as clinically indicated.<br><br>          5. No history of distant metastases.<br><br>          6. Tumor tissue from surgery or biopsy must be available to determine MAGE-A3 expression<br>             for correlative studies.<br><br>          7. Following surgery, the patient must have received external beam radiotherapy (58-66 Gy<br>             in 2 Gy fractions, 5 days per week) with concomitant cisplatin starting within 8 weeks<br>             of surgery. A brief delay in the initiation of radiotherapy following 8 weeks<br>             post-surgery due to administrative reasons (e.g., start of RT on Mondays) may be<br>             permitted by the Medical Monitor. The cumulative dose of cisplatin the subject<br>             received must be > 150 mg/m2. Protocol therapy must be initiated within a period of<br>             4-8 weeks (28-56 days) following the end of RT.<br><br>          8. The patient is, in the investigator's opinion, adequately recovered from the effects<br>             of surgery and chemoradiotherapy to participate in this study.<br><br>          9. Blood HLA-A2 phenotype<br><br>         10. ECOG Performance Status < 1<br><br>         11. Laboratory values obtained = 14 days prior to randomization:<br><br>               -  Absolute neutrophil count (ANC) = 1500/µL (without intervention, e.g., G-CSF)<br><br>               -  Platelets = 75,000/µL (without intervention, e.g., transfusion)<br><br>               -  Hemoglobin = 8.0 g/dl (Note: The use of transfusion or other intervention to<br>                  achieve Hgb =8.0 g/dl is acceptable).<br><br>               -  Alkaline phosphatase = 2.5 x upper limit of normal (ULN)<br><br>               -  AST and ALT = 2 x ULN<br><br>               -  Creatinine < 2 x ULN<br><br>               -  Bilirubin < 1.5x ULN (except for patients with Gilbert's disease, for whom the<br>                  upper acceptable limit of serum bilirubin is 3mg/dL)<br><br>         12. A female subject is eligible to enter the study if she is:<br><br>               -  not pregnant or nursing; Female participants must not breastfeed during the study<br>                  and for a period of 30 days following the last dose.<br><br>               -  of non-childbearing potential (i.e., women who had a hysterectomy, are<br>                  postmenopausal which is defined as 1 year without menses, have both ovaries<br>                  surgically removed or have current documented tubal ligation); or<br><br>               -  of childbearing potential (i.e., women with functional ovaries and no documented<br>                  impairment of oviductal or uterine function that would cause sterility). This<br>                  category includes women with oligomenorrhea [even severe], women who are<br>                  perimenopausal or have just begun to menstruate. These women must have a negative<br>                  serum pregnancy test at screening, and agree to one of the following:<br><br>                    -  complete abstinence from intercourse from 2 weeks prior to administration of<br>                       the 1st dose of study agent and 6 months after the last dose of study agent;<br>                       or<br><br>                    -  consistent and correct use of 1 of the following highly effective methods of<br>                       birth control for one month prior to the start of the study agent and 6<br>                       months after the last dose:<br><br>               -  combined (estrogen and progestogen containing) hormonal contraception associated<br>                  with inhibition of ovulation (oral, intravaginal, transdermal)<br><br>               -  progestogen-only hormonal contraception associated with inhibition of ovulation<br>                  (oral, injectable, implantable)<br><br>               -  intrauterine device (IUD)<br><br>               -  intrauterine hormone-releasing system ( IUS)<br><br>               -  bilateral tubal occlusion<br><br>               -  vasectomized partner (if vasectomized is the sole sexual partner and has received<br>                  medical confirmation of surgical success)<br><br>         13. A male subject who is sexually active with a woman of childbearing potential is<br>             eligible to enter the study if he agrees to use effective contraception throughout the<br>             study and for 6 months after the last dose of study agent.<br><br>         14. The subject must be capable of understanding the investigational nature, potential<br>             risks and benefits of the study and capable of providing valid informed consent. The<br>             subject must provide study specific informed consent prior to any protocol procedures<br>             that are not a part of standard care, including consent for assessment of HLA-A2<br>             status, mandatory tissue submission for MAGE-A3 analysis and correlative studies.<br><br>         15. The subject must be willing to return to the study center for vaccinations and<br>             study-related follow up procedures including blood and tumor collections and<br>             completion of imaging studies as required by the protocol.<br><br>        Exclusion Criteria:<br><br>          1. Known HIV or hepatitis B/C infection (testing not required). Subjects who are<br>             hepatitis C antibody positive may be enrolled if they are confirmed to have a negative<br>             viral load at screening.<br><br>          2. Subjects with active autoimmune disease or a history of autoimmune disease requiring<br>             systemic steroids or other immunosuppressive treatment.<br><br>          3. Subjects who have used systemic corticosteroids or other immunosuppressants for any<br>             condition within 14 days of randomization. Inhaled or topical steroids are permitted.<br><br>          4. Any medical condition which would, in the investigator's opinion, compromise the<br>             patient's ability to mount an immune response, renders the patient a poor candidate<br>             for this trial or could confound the results of the study<br><br>          5. Major surgery or traumatic injury within 28 days of randomization<br><br>          6. Prior splenectomy or organ allograft<br><br>          7. Any other prior, concurrent or planned chemotherapy, immunotherapy, radiotherapy,<br>             device, or investigational therapy for this cancer other than those specified in this<br>             study.<br><br>          8. History of other malignancy (i.e., excluding disease under study) within 3 years of<br>